For most surface reactive liposome formulations, the reactive lipid is incorporated into the liposomes and the ligand, protein or peptide is conjugated directly to the liposomes that contain reactive lipids. However, this strategy might not work if the reactive lipid is prone to hydrolysis such as maleimide or NHS lipid. In order to get around this issue, the liposomes are made without the PEGylated (reactive and non-reactive) lipids. The scientist who is planning to use the kit will conjugate the ligand, protein or peptide to the reactive lipid. Next, the buffer is added to the lipid-conjugated ligand and micelle solution is formed. Another micelle solution is formed after the PEGylated non-reactive lipid is hydrated with the buffer. The two micelle solutions are mixed and incubated together at a temperature above the liquid-to-gel phase transition temperature of the HSPC (saturated matrix lipid). The PEGylated lipids in the micelles insert themselves with a high efficiency (above 80%) to the liposomes and form the immunoliposomes.
Surface reactive doxorubicin liposomes (using various types of chemistries) suitable for conjugation of various antibodies, proteins, peptides and ligands are also available. For more information about surface reactive doxorubicin liposomes (Immundox®) see here.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
采用抗-HBe抗体包被反应板，加入校准品及被测样本，同时加入定量HBeAg中和抗原，经过振荡孵育,洗板后再加入铕标记的抗-HBe，若标本中抗-HBe浓度高，HBeAg将被大量中和，使最后形成的抗-HBe-HBeAg-铕标记抗-HBe复合物减少。增强液（β－NTA）将标记在抗体上的Eu3+解离到溶液中，Eu3+和增强液中的有效成分形成高荧光强度的螯合物，荧光强度和样本中的抗-HBe浓度成反比。
